Steckel H, Markefka P, TeWierik H, Kammelar R
Department of Pharmaceutics and Biopharmaceutics, Christian Albrecht University of Kiel, Kiel, Germany.
Eur J Pharm Biopharm. 2004 May;57(3):495-505. doi: 10.1016/j.ejpb.2003.12.003.
Lactose monohydrate for inhalation is commonly produced by sieving out customer-specific size fractions of a crystallized bulk material of lactose. It was the aim of this study to investigate the influence of the raw material on the physico-chemical properties of the inhalation grade lactose and on the efficacy of powders for inhalation produced from these batches. The selected raw material lactose batches differed in the size distribution characteristics, the fines and the agglomerate content. These differences in the raw material could also be found to a smaller extent in the intermediate products and could not be completely levelled out in the final inhalation grade lactose. Efficiency testing was done using salbutamol sulphate in two different concentrations (drug-to-carrier ratio of 1:36 and 1:400) as a model drug; the powder blends were delivered using the Aerolizer and the Easyhaler device. With the high drug load, nearly no differences could be observed between both the delivery systems and the different produced lactose batches. The fine particle fraction (FPF) (%<5 microm) was on a high level of >39% in all cases. With the low drug load significant differences between the devices and the lactose batches were found. The FPF was distinctly reduced to 15-30%, with the Easyhaler generating a higher fraction of fine particles than the Aerolizer device. Although the observed differences between the lactose batches could not be linked to one specific physico-chemical parameter determined for the carrier, they led to the conclusion that the differences between the test batches of inhalation grade lactose especially manufactured for this study can affect the functionality of an inhalation powder. The effects are significantly smaller with high drug load formulations than using a low drug concentration.
吸入用乳糖一水合物通常是通过筛选出乳糖结晶块状物料中客户特定的粒度级分来生产的。本研究的目的是调查原料对吸入级乳糖物理化学性质以及由这些批次生产的吸入粉雾剂疗效的影响。所选的原料乳糖批次在粒度分布特征、细粉和团聚物含量方面存在差异。在中间产品中也能在较小程度上发现原料的这些差异,并且在最终的吸入级乳糖中无法完全消除。使用两种不同浓度(药物与载体比例为1:36和1:400)的硫酸沙丁胺醇作为模型药物进行效率测试;使用Aerolizer和Easyhaler装置递送混合粉末。在高药物负载下,两种递送系统和不同生产的乳糖批次之间几乎没有观察到差异。所有情况下细颗粒分数(FPF)(<5微米的百分比)都处于>39%的高水平。在低药物负载下,发现装置和乳糖批次之间存在显著差异。FPF明显降低至15 - 30%,Easyhaler产生的细颗粒分数高于Aerolizer装置。尽管观察到的乳糖批次之间的差异无法与为载体测定的一个特定物理化学参数相关联,但得出的结论是,专门为本研究生产的吸入级乳糖测试批次之间的差异会影响吸入粉雾剂的功能。高药物负载制剂的影响明显小于使用低药物浓度时的影响。